This is a very dangerous assumption. There just isn't enough data or research (especially on people with tinnitus or who already have visual snow) to assume. Yes, the fact that it's significantly safer than Retigabine is true. However, we won't know for certain until people try it out. The mechanisms of visual snow are unknown. Yes, the side effects results from the clinical trials are not bad at all, but in any case people should be wary. The subjects in the XEN1101 trial did not have tinnitus, as far as I can tell. However, I would assume some might have had it to some degree, due to it being such a common condition. The dosages of Retigabine were massive. Some were taking up to 900 mg a day, which is ginormous compared to the 10-20 mg of XEN1101. It also hit many potassium channels. My theory as to why some people didn't see as much effect as others is the exact potassium channels being modified for everyone in such a broad drug was very different; some had their KCNQ2/KCNQ3 affected more than others. People have to be careful with a drug like this, especially if they show signs of visual snow, even mild. We are wired differently than people with epilepsy.